In the high-stakes world of biopharma, few stories are as compelling as the race to develop a successor to a multi-billion-dollar drug. We're joined today by Ivan Kairatov, a biopharma expert with deep experience in research, development, and the intricate dance between clinical data and commercial
The relentless cycle of flare-ups for those with severe Chronic Obstructive Pulmonary Disease has long demanded a more precise therapeutic weapon, a need the UK's health authorities have now addressed with a new approval. This review evaluates Nucala (mepolizumab), recently authorized by the MHRA
In the fast-evolving world of immunology, the race to develop a highly effective oral treatment for psoriasis has reached a fever pitch. With the recent success of Alumis's Phase 3 trials for envudeucitinib, the landscape is poised for a significant shift. We sat down with biopharma expert Ivan
With the recent FDA approval of Novo Nordisk's oral version of Wegovy, the landscape of weight management treatment is poised for a monumental shift. We sat down with biopharma expert Ivan Kairatov, whose extensive background in research and development offers a unique lens on this
For the first time in more than a decade, the therapeutic landscape for newly diagnosed metastatic HER2-positive breast cancer has been fundamentally altered by a landmark U.S. Food and Drug Administration decision. The agency has officially approved a combination therapy featuring Enhertu and
The landscape of oncology treatment is witnessing a transformative shift with Johnson & Johnson (J&J) securing a positive recommendation from the UK’s National Institute for Health and Care Excellence (NICE) for its groundbreaking therapy, TALVEY (talquetamab). This approval for use within the
